MINNEAPOLIS--(BUSINESS WIRE)--Building on its reputation for excellence in the deliverability of its angioplasty products, Medtronic, Inc. (NYSE: MDT), announced today the U.S. market launch of the Endeavor Sprint drug-eluting stent (DES) on a rapid exchange (RX) delivery system.
